The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Signatures of mutational processes in human cancer
Open accessAbstract
All cancers are caused by somatic mutations; however, understanding of the biological processes generating these mutations is limited. The catalogue of somatic mutations from a cancer genome bears the signatures of the mutational processes that have been operative. Here we analysed 4,938,362 mutations from 7,042 cancers and extracted more than 20 distinct mutational signatures. Some are present in many cancer types, notably a signature attributed to the APOBEC family of cytidine deaminases, whereas others are confined to a single cancer class. Certain signatures are associated with age of the patient at cancer diagnosis, known mutagenic exposures or defects in DNA maintenance, but many are of cryptic origin. In addition to these genome-wide mutational signatures, hypermutation localized to small genomic regions, 'kataegis', is found in many cancer types. The results reveal the diversity of mutational processes underlying the development of cancer, with potential implications for understanding of cancer aetiology, prevention and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of TAA-derived epitopes has the advantage of allowing development of an off-the-shelf product for a tumour indication with low mutational burden such as GBM, where patients’ tumours express only few tumour-specific antigens [38].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredIn the citing paper
“In MM, SBS9, associated with mutations introduced by polymerase η repair of activation-induced deaminase (AID) activity26,31,32, was strongly linked with Q61H”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [26]
In the citing paper
“Five substitution and five rearrangement signatures [8, 9] were identified”
From Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers (2019) · cites this paper as [8]
In the citing paper
“a high SNV burden associated with APOBEC substitution signature [8]”
From Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers (2019) · cites this paper as [8]
In the citing paper
“It has also been noted that the 'pol h mutational signature' (Signature 9; http://cancer.sanger.ac.uk/cosmic/sig natures) occurs in chronic lymphocytic leukemia and malignant Bcell lymphoma genomes 6,26,27 .”
From DNA polymerase η mutational signatures are found in a variety of different types of cancer (2018) · cites this paper as [6]
In the citing paper
“Several distinct mutational signatures sculpt the genome of NSCLC – including signatures of tobacco exposure and APOBEC-mediated cytidine deamination57.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [57]
In the citing paper
“Melanoma somatic mutations consist almost entirely of C → T transitions, 28% of which are TCC → T mutations (19,31).”
From Evidence for recent, population-specific evolution of the human mutation rate (2015) · cites this paper as [19]
In the citing paper
“Excess C → T transitions are characteristic of several different mutagenic processes including UV damage and cytosine deamination (19).”
From Evidence for recent, population-specific evolution of the human mutation rate (2015) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationStratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
Self-citationSomatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Self-citationThe Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541
Self-citationThe mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Cited by
Sorted by citations
Items 901–1,000 of 1,100
Break-Induced Replication Is a Source of Mutation Clusters Underlying Kataegis
Sakofsky, C. J., Roberts, S. A., Malc, E. P., Mieczkowski, P. A., Resnick, M. A., Gordenin, D. A., & Malkova, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.053 · Cited by 170
Tackling the Diversity of Triple-Negative Breast Cancer
Turner, N. C., & Reis-Filho, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0915 · Cited by 175
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 175
The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169
Measuring cancer evolution from the genome
Graham, T. A., & Sottoriva, A. (2016) · The Journal of Pathology · doi:10.1002/path.4821 · Cited by 182
Menghi, F., Barthel, F. P., Yadav, V. K., Tang, M., Ji, B., Tang, Z., Carter, G. W., Ruan, Y., Scully, R., Verhaak, R. G. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.008 · Cited by 179
Knepper, T. C., Montesion, M., Russell, J. S., Sokol, E. S., Frampton, G. M., Miller, V. A., Albacker, L. A., McLeod, H. L., Eroglu, Z., Khushalani, N. I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4159 · Cited by 172
Zhu, Z., Zhang, H., Chen, B., Liu, X., Zhang, S., Zong, Z., & Gao, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588552 · Cited by 173
Vandekerkhove, G. R., Lavoie, J., Annala, M., Murtha, A. J., Sundahl, N., Walz, S., Sano, T., Taavitsainen, S., Ritch, E. J., Fazli, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20493-6 · Cited by 174
Pilati, C., Shinde, J., Alexandrov, L. B., Assié, G., André, T., Hélias‐Rodzewicz, Z., Ducoudray, R., Le Corre, D., Zucman‐Rossi, J., Emile, J., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4880 · Cited by 150
Self-citationFidelity of DNA replication—a matter of proofreading
Bębenek, A., & Ziuzia-Graczyk, I. (2018) · Current Genetics · doi:10.1007/s00294-018-0820-1 · Cited by 168
Mechanisms of Genomic Instability in Breast Cancer
Duijf, P. H. G., Nanayakkara, D. M., Nones, K., Srihari, S., Kalimutho, M., & Khanna, K. K. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.04.004 · Cited by 171
The landscape of chromothripsis across adult cancer types
Voronina, N., Wong, J., Hübschmann, D., Hlevnjak, M., Uhrig, S., Heilig, C. E., Horak, P., Kreutzfeldt, S., Möck, A., Stenzinger, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16134-7 · Cited by 170
Self-citationCristescu, R., Aurora-Garg, D., Albright, A. V., Xu, L., Liu, X. Q., Loboda, A. P., Lang, L., Jin, F., Rubin, E. H., Snyder, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003091 · Cited by 172
TP53Mutations in Breast and Ovarian CancerPreprint
Silwal‐Pandit, L., Langerød, A., & Børresen‐Dale, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026252 · Cited by 177
Self-citationTranslating cancer genomes and transcriptomes for precision oncology
Roychowdhury, S., & Chinnaiyan, A. M. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21329 · Cited by 168
Jones, S., Stransky, N., McCord, C. L., Cerami, E. G., Lagowski, J. P., Kelly, D. D., Angiuoli, S. V., Sausen, M., Kann, L. M., Shukla, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6006 · Cited by 169
Genomic landscape of DNA repair genes in cancer
Chae, Y. K., Anker, J. F., Carneiro, B. A., Chandra, S., Kaplan, J. B., Kalyan, A., Santa-Maria, C. A., Platanias, L. C., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8196 · Cited by 174
POSTAR: a platform for exploring post-transcriptional regulation coordinated by RNA-binding proteins
Hu, B., Yang, Y., Huang, Y., Zhu, Y., & Lu, Z. J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw888 · Cited by 169
APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis
Maciejowski, J., Chatzipli, A., Dananberg, A., Chu, K., Toufektchan, E., Klimczak, L. J., Gordenin, D. A., Campbell, P. J., & de Lange, T. (2020) · Nature Genetics · doi:10.1038/s41588-020-0667-5 · Cited by 167
Self-citationAaes, T. L., & Vandenabeele, P. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00658-y · Cited by 169
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0013-8 · Cited by 166
Chafe, S. C., McDonald, P. C., Saberi, S., Nemirovsky, O., Venkateswaran, G., Burugu, S., Gao, D., Delaidelli, A., Kyle, A. H., Baker, J. H. E., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0657 · Cited by 168
Kumar, S., Warrell, J., Li, S., McGillivray, P. D., Meyerson, W. U., Salichos, L., Harmanci, A. O., Martinez‐Fundichely, A., Chan, C. W. Y., Nielsen, M. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.032 · Cited by 174
Pleasance, E., Titmuss, E., Williamson, L., Kwan, H., Culibrk, L., Stutheit-Zhao, E. Y., Dixon, K., Fan, K. Y., Bowlby, R., Jones, M. R., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0050-6 · Cited by 174
Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy
Schrempf, A., Slyšková, J., & Loizou, J. I. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.09.007 · Cited by 172
Evidence for recent, population-specific evolution of the human mutation rate
Harris, K. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418652112 · Cited by 165
Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma
Zhang, W., He, H., Zang, M., Wu, Q., Zhao, H., Lu, L.-L., Ma, P., Zheng, H., Wang, N.-J., Zhang, Y., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.024 · Cited by 169
Prokocimer, M., Molchadsky, A., & Rotter, V. (2017) · Blood · doi:10.1182/blood-2017-02-763086 · Cited by 172
Choucair, K., Morand, S. M., Stanbery, L., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 170
Molecular determinants of response to PD-L1 blockade across tumor types
Banchereau, R., Leng, N., Zill, O. A., Sokol, E. S., Liu, G., Pavlick, D., Maund, S. L., Liu, L.-F., Kadel, E. E., Baldwin, N. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24112-w · Cited by 167
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Timing the Initiation of Multiple Myeloma
Rustad, E. H., Yellapantula, V., Leongamornlert, D., Bolli, N., Ledergor, G., Nadeu, F., Angelopoulos, N., Dawson, K. J., Mitchell, T. J., Osborne, R. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15740-9 · Cited by 165
Self-citationAPOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma
Leonard, B. C., Hart, S. N., Burns, M. B., Carpenter, M. A., Temiz, N. A., Rathore, A. S., Vogel, R. I., Nikas, J. B., Law, E. K., Brown, W. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1753 · Cited by 164
Biomarkers associated with checkpoint inhibitors
Manson, G., Norwood, J., Marabelle, A., Kohrt, H. E. K., & Houot, R. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw181 · Cited by 166
Wang, R., Song, S., Harada, K., Amlashi, F. G., Badgwell, B. D., Pizzi, M. P., Xu, Y., Zhao, W., Dong, X., Jin, J., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-318070 · Cited by 165
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations
Brady, S. W., Liu, Y., Ma, X., Gout, A. M., Hagiwara, K., Zhou, X., Wang, J., Macias, M., Chen, X., Easton, J. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18987-4 · Cited by 170
Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA
Bergstrom, E. N., Luebeck, J., Petljak, M., Khandekar, A., Barnes, M. D., Zhang, T., Steele, C. D., Pillay, N., Landi, M. T., Bafna, V., et al. (2022) · Nature · doi:10.1038/s41586-022-04398-6 · Cited by 166
Self-citationCuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer
Song, Q., Zhou, R., Shu, F., & Wen, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958368 · Cited by 165
Protein oxidation, UVA and human DNA repair
Karran, P., & Brem, R. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.05.024 · Cited by 168
TRIC: an automated alignment strategy for reproducible protein quantification in targeted proteomics
Röst, H. L., Liu, Y., D’Agostino, G. A., Zanella, M., Navarro, P., Rosenberger, G., Collins, B. C., Gillet, L. C. J., Testa, G., Malmström, L., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3954 · Cited by 166
Craven, K. E., Gökmen‐Polar, Y., & Badve, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83913-7 · Cited by 163
Therapy-induced APOBEC3A drives evolution of persistent cancer cells
Isozaki, H., Sakhtemani, R., Abbasi, A., Nikpour, N., Stanzione, M., Oh, S., Langenbucher, A., Monroe, S., Su, W., Cabanos, H. F., et al. (2023) · Nature · doi:10.1038/s41586-023-06303-1 · Cited by 168
Vater, I., Montesinos‐Rongen, M., Schlesner, M., Haake, A., Purschke, F., Sprute, R., Mettenmeyer, N., Nazzal, I., Nagel, I., Gutwein, J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.264 · Cited by 167
Self-citationHigh-Definition Reconstruction of Clonal Composition in Cancer
Fischer, A., Vázquez-Garćıa, I., Illingworth, C. J. R., & Mustonen, V. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.055 · Cited by 166
Myeloproliferative neoplasms: from origins to outcomes
Nangalia, J., & Green, A. R. (2017) · Blood · doi:10.1182/blood-2017-06-782037 · Cited by 167
Evolutionary history of human colitis-associated colorectal cancer
Baker, A., Cross, W. C. H., Curtius, K., Bakir, I. A., Choi, C.-H. R., Belnoue-Davis, H. L., Temko, D., Biswas, S., Martinez, P., Williams, M. J., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316191 · Cited by 168
Local Determinants of the Mutational Landscape of the Human Genome
González-Pérez, A., Sabarinathan, R., & López-Bigas, N. (2019) · Cell · doi:10.1016/j.cell.2019.02.051 · Cited by 172
Wang, Q., Li, M., Yang, M., Yang, Y., Song, F., Zhang, W., Li, X., & Chen, K. (2020) · Aging · doi:10.18632/aging.102814 · Cited by 164
The mutational signature profile of known and suspected human carcinogens in mice
Riva, L., Pandiri, A. R., Li, Y. R., Droop, A., Hewinson, J., Quail, M. A., Iyer, V., Shepherd, R., Herbert, R. A., Campbell, P. J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0692-4 · Cited by 169
Self-citationPatient-derived xenografts and organoids model therapy response in prostate cancer
Karkampouna, S., Manna, F. L., Benjak, A., Kiener, M., Menna, M. D., Zoni, E., Grosjean, J., Klima, I., Garofoli, A., Bolis, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21300-6 · Cited by 162
The origins, determinants, and consequences of human mutations
Shendure, J., & Akey, J. M. (2015) · Science · doi:10.1126/science.aaa9119 · Cited by 167
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Ng, C. K. Y., Piscuoglio, S., Geyer, F. C., Burke, K. A., Pareja, F. G., Eberle, C. A., Lim, R. S., Natrajan, R., Riaz, N., Mariani, O., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2857 · Cited by 164
Self-citationCombating subclonal evolution of resistant cancer phenotypes
Brady, S. W., McQuerry, J. A., Qiao, Y., Piccolo, S., Shrestha, G., Jenkins, D. F., Layer, R. M., Pedersen, B. S., Miller, R. H., Esch, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01174-3 · Cited by 163
Sprouse, M. L., Welte, T., Boral, D., Liu, H. N., Yin, W., Vishnoi, M., Goswami-Sewell, D., Li, L., Pei, G., Jia, P., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081916 · Cited by 165
Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial
Riaz, N., Sherman, E. J., Pei, X., Schöder, H. M., Grkovski, M., Paudyal, R., Katabi, N., Selenica, P., Yamaguchi, T. N., Ma, D. J., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa184 · Cited by 161
RTCGAToolbox: A New Tool for Exporting TCGA Firehose Data
Samur, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106397 · Cited by 161
Sequencing small genomic targets with high efficiency and extreme accuracy
Schmitt, M. W., Fox, E. J., Prindle, M. J., Reid-Bayliss, K. S., True, L. D., Radich, J. P., & Loeb, L. A. (2015) · Nature Methods · doi:10.1038/nmeth.3351 · Cited by 160
Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer
Rao, C. V., Asch, A. S., & Yamada, H. Y. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw118 · Cited by 163
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K.-F., Bailey, P. J., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 168
Self-citationImmune Checkpoints as a Target for Colorectal Cancer Treatment
Passardi, A., Canale, M., Valgiusti, M., & Ulivi, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061324 · Cited by 168
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Jia, Q., Wang, J., He, N., He, J., & Zhu, B. (2019) · JCI Insight · doi:10.1172/jci.insight.127901 · Cited by 162
TGFβ Signaling in Photoaging and UV-Induced Skin Cancer
Ke, Y., & Wang, X. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.007 · Cited by 160
Somatic Mutations in “Benign” Disease
Mustjoki, S. M., & Young, N. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2101920 · Cited by 169
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls
Horak, P., Fröhling, S., & Glimm, H. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000094 · Cited by 162
APOBEC Enzymes as Targets for Virus and Cancer Therapy
Olson, M. E., Harris, R. S., & Harki, D. A. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.007 · Cited by 164
NRAS mutant melanoma: Towards better therapies
Randic, T., Kozar, I., Margue, C., Utikal, J. S., & Kreis, S. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102238 · Cited by 170
Subudhi, S. K., Vence, L., Zhao, H., Blando, J., Yadav, S. S., Xiong, Q., Reuben, A., Aparicio, A., Corn, P. G., Chapin, B. F., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3577 · Cited by 158
PARP Inhibitors in Ovarian Cancer
Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666180305165256 · Cited by 158
Jones, M. R., Williamson, L., Topham, J. T., Lee, M. K. C., Goytain, A., Ho, J., Denroche, R. E., Jang, G.-H., Pleasance, E., Shen, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0191 · Cited by 160
3D genomic mapping reveals multifocality of human pancreatic precancers
Braxton, A. M., Kiemen, A. L., Grahn, M. P., Forjaz, A., Parksong, J., Babu, J. M., Lai, J., Zheng, L., Niknafs, N., Jiang, L., et al. (2024) · Nature · doi:10.1038/s41586-024-07359-3 · Cited by 165
The causes of replication stress and their consequences on genome stability and cell fate
Magdalou, I., López, B. S., Pasero, P., & Lambert, S. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.04.035 · Cited by 183
The importance of DNA methylation in prostate cancer development
Massie, C. E., Mills, I. G., & Lynch, A. G. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.009 · Cited by 163
Chitsazzadeh, V., Coarfa, C., Drummond, J., Nguyen, T. M., Joseph, A. K., Chilukuri, S., Charpiot, E., Adelmann, C. H., Ching, G., Nguyen, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12601 · Cited by 162
DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer
Kanu, N., Cerone, M. A., Goh, G., Zalmas, L., Bártková, J., Dietzen, M., McGranahan, N., Rogers, R. F., Law, E. K., Gromova, I., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1042-9 · Cited by 162
Nowak, J. A., Yurgelun, M. B. B., Bruce, J. L., Rojas‐Rudilla, V., Hall, D. L., Shivdasani, P., Garcia, E. P., Agoston, A. T., Srivastava, A., Ogino, S., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.07.010 · Cited by 160
Bobisse, S., Genolet, R., Roberti, A., Tanyi, J. L., Racle, J., Stevenson, B. J., Iseli, C., Michel, A., Bitoux, M. L., Guillaume, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03301-0 · Cited by 165
Identification of recurrent USP48 and BRAF mutations in Cushing’s disease
Chen, J., Jian, X., Deng, S., Ma, Z., Shou, X., Shen, Y., Zhang, Q., Song, Z., Li, Z., Peng, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05275-5 · Cited by 157
Wienand, K., Chapuy, B., Stewart, C., Dunford, A. J., Wu, D., Kim, J., Kamburov, A., Wood, T. R., Cader, F. Z., Ducar, M. D., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019001012 · Cited by 160
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
Saltos, A. N., Shafique, M. R., & Chiappori, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01074 · Cited by 160
Patterns of within-host genetic diversity in SARS-CoV-2
Tonkin-Hill, G., Martincorena, I., Amato, R., Lawson, A. R. J., Gerstung, M., Johnston, I., Jackson, D. K., Park, N. R., Lensing, S. V., Quail, M. A., et al. (2021) · eLife · doi:10.7554/elife.66857 · Cited by 161
Das, A., Sudhaman, S., Morgenstern, D. A., Coblentz, A. C., Chung, J., Stone, S. C., Alsafwani, N. S., Liu, Z. A., Karsaneh, O. A. A., Soleimani, S., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01581-6 · Cited by 165
Park, J. S., Lee, J., Jung, E. S., Kim, M.-H., Kim, I. B., Son, H., Kim, S., Kim, S., Park, Y. M., Mook-Jung, I., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11000-7 · Cited by 155
Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution
Uchi, R., Takahashi, Y., Niida, A., Shimamura, T., Hirata, H., Sugimachi, K., Sawada, G., Iwaya, T., Kurashige, J., Shinden, Y., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005778 · Cited by 159
Self-citationImmune checkpoint inhibition in ovarian cancer
Hamanishi, J., Mandai, M., & Konishi, I. (2016) · International Immunology · doi:10.1093/intimm/dxw020 · Cited by 158
Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia
Gassner, F. J., Schubert, M., Rebhandl, S., Spandl, K., Zaborsky, N., Catakovic, K., Blaimer, S., Hebenstreit, D., Greil, R., & Geisberger, R. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0373 · Cited by 156
The critical roles of somatic mutations and environmental tumor-promoting agents in cancer risk
Balmain, A. (2020) · Nature Genetics · doi:10.1038/s41588-020-00727-5 · Cited by 152
Molecular mechanisms of the preventable causes of cancer in the United StatesPreprint
Golemis, E. A., Scheet, P. A., Beck, T. N., Scolnick, E. M., Hunter, D. J., Hawk, E. T., & Hopkins, N. H. (2018) · Genes & Development · doi:10.1101/gad.314849.118 · Cited by 164
Genomic landscape of adenoid cystic carcinoma of the breast
Martelotto, L. G., Filippo, M. R. D., Ng, C. K. Y., Natrajan, R., Fuhrmann, L., Cyrta, J., Piscuoglio, S., Wen, H., Lim, R. S., Shen, R., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4573 · Cited by 157
Self-citationKrimmel‐Morrison, J. D., Schmitt, M. W., Harrell, M. I., Agnew, K. J., Kennedy, S. R., Emond, M. J., Loeb, L. A., Swisher, E. M., & Risques, R. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601311113 · Cited by 160
Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy
Rapoport, B. L., & Anderson, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040959 · Cited by 156
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
Loeffler, M. W., Mohr, C., Bichmann, L., Freudenmann, L. K., Walzer, M., Schroeder, C., Trautwein, N., Hilke, F. J., Zinser, R. S., Mühlenbruch, L., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0636-8 · Cited by 157
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
Jones, D., Banito, A., Grünewald, T. G. P., Haber, M., Jäger, N., Kool, M., Milde, T., Molenaar, J. J., Nabbi, A., Pugh, T. J., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0169-x · Cited by 161
Self-citationMolecular profiling of driver events in metastatic uveal melanoma
Karlsson, J. W., Nilsson, L. M., Mitra, S., Alsén, S., Shelke, G. V., Sah, V. R., Forsberg, E. M. V., Stierner, U. K., All‐Eriksson, C., Einarsdottir, B. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15606-0 · Cited by 155
Golan, T., O'Kane, G. M., Denroche, R. E., Raitses‐Gurevich, M., Grant, R. C., Holter, S., Wang, Y., Zhang, A. X. W., Jang, G. H., Stossel, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.220 · Cited by 157
Basurto‐Lozada, P., Molina‐Aguilar, C., Castaneda‐Garcia, C., Vázquez‐Cruz, M. E., Garcia‐Salinas, O. I., Álvarez‐Cano, A., Martínez‐Said, H., Roldán‐Marín, R., Adams, D. J., Possik, P. A., et al. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12885 · Cited by 154
Trial watch: Peptide-based vaccines in anticancer therapy
Bezu, L., Kepp, O., Cerrato, G., Pol, J. G., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1511506 · Cited by 158
The genomic and transcriptional landscape of primary central nervous system lymphoma
Radke, J., Ishaque, N., Koll, R., Gu, Z., Schumann, E., Sieverling, L., Uhrig, S., Hübschmann, D., Toprak, U. H., López, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30050-y · Cited by 158
Self-citationRecurrent or primary metastatic cervical cancer: current and future treatments
Gennigens, C., Jérusalem, G., Lapaille, L., Cuypere, M. D., Streel, S., Kridelka, F., & Ray-Coquard, I. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100579 · Cited by 156
Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?
Bowden, N. A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.005 · Cited by 154
Metadata
- Authors
- Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Børresen-Dale, A.-L., Boyault, S., Burkhardt, B., Butler, A. P., Caldas, C., Davies, H. R., Desmedt, C., Eils, R., Eyfjörd, J. E., Foekens, J. A., Greaves, M., Hosoda, F., Hutter, B., Ilicic, T., Imbeaud, S., Imielinski, M., Jäger, N., Jones, D. T. W., Jones, D., Knappskog, S., Kool, M., Lakhani, S. R., López-Otín, C., Martin, S., Munshi, N. C., Nakamura, H., Northcott, P. A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J. V., Puente, X. S., Raine, K., Ramakrishna, M., Richardson, A. L., Richter, J., Rosenstiel, P., Schlesner, M., Schumacher, T. N., Span, P. N., Teague, J. W., Totoki, Y., Tutt, A. N. J., Valdés-Mas, R., van Buuren, M. M., van ’t Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L. R., Zucman-Rossi, J., Andrew Futreal, P., McDermott, U., Lichter, P., Meyerson, M., Grimmond, S. M., Siebert, R., Campo, E., Shibata, T., Pfister, S. M., Campbell, P. J., & Stratton, M. R.
- Affiliations
- Wellcome Sanger Institute (GB)
- BC Cancer Agency (CA)
- University of Cambridge (GB)
- Garvan Institute of Medical Research (AU)
- Lund University (SE)
- Oslo University Hospital (NO)
- Justus-Liebig-Universität Gießen (DE)
- Université Libre de Bruxelles (BE)
- German Cancer Research Center (DE)
- Erasmus MC Cancer Institute (NL)
- Inserm (FR)
- Broad Institute (US)
- The University of Queensland (AU)
- Universidad de Oviedo (ES)
- Harvard University (US)
- National Cancer Center Research Institute (JP)
- University of Glasgow (GB)
- Brigham and Women's Hospital (US)
- The Netherlands Cancer Institute (NL)
- Radboud University Medical Center (NL)
- King's College London (GB)
- Christian-Albrechts-Universität zu Kiel (DE)
- Corresponding author
- Stratton, Michael R.
- ORCID
- Alexandrov, Ludmil B.
- Wedge, David C.
- Aparicio, Samuel A. J. R.
- Behjati, Sam
- Biankin, Andrew V.
- Bolli, Niccolò
- Boyault, Sandrine
- Burkhardt, Birgit
- Caldas, Carlos
- Davies, Helen R.
- Desmedt, Christine
- Eils, Roland
- Hutter, Barbara
- Imbeaud, Sandrine
- Imielinski, Marcin
- Jäger, Natalie
- Knappskog, Stian
- Kool, Marcel
- Lakhani, Sunil R.
- Martin, Sancha
- Munshi, Nikhil C.
- Nakamura, Hiromi
- Northcott, Paul A.
- Pajic, Marina
- Papaemmanuil, Elli
- Paradiso, Angelo
- Pearson, John V.
- Raine, Keiran
- Ramakrishna, Manasa
- Richardson, Andrea L.
- Richter, Julia
- Rosenstiel, Philip
- Schlesner, Matthias
- Schumacher, Ton N.
- Span, Paul N.
- Teague, Jon W.
- Totoki, Yasushi
- Tutt, Andrew N. J.
- Waddell, Nicola
- Yates, Lucy R.
- McDermott, Ultan
- Meyerson, Matthew
- Grimmond, Sean M.
- Siebert, Reiner
- Shibata, Tatsuhiro
- Pfister, Stefan M.
- Campbell, Peter J.
- Stratton, Michael R.
- Venue
- Nature
- Published
- 2013-08-14
- Volume
- 500
- Issue
- 7463
- Pages
- 415-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3776390
- OpenAlex
- W2152061559
- Cited by
- 9,660
- References
- 67
- Citations by year
- 2026: 384 · 2025: 552 · 2024: 643 · 2023: 854 · 2022: 921 · 2021: 1119 · 2020: 1130 · 2019: 939 · 2018: 873 · 2017: 815 · 2016: 660 · 2015: 421 · 2014: 286 · 2013: 45
- FWCI
- 165.61
- Type
- journal article
- Language
- en
- Update notices
- erratum (2013-10-09)
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Deutsches Krebsforschungszentrum (69120)
- Wellcome Trust (088340, 093867, 098051)
- Broad Institute
- Canada's Michael Smith Genome Sciences Centre
- Cancer Research UK
- University of Glasgow
- Agence Nationale de la Recherche (ANR-10-LABX-0015)
- Institut National de la Santé et de la Recherche Médicale
- University of New South Wales
- Lunds Universitet
- Universitetet i Oslo
- Háskóli Íslands
- Universitat de Barcelona
- BC Cancer Agency
- Labex Immuno-Oncology
- Medisinske fakultet, Universitetet i Oslo
- Cancer Research UK Cambridge Institute, University of Cambridge
- National Cancer Institute (T32CA009216)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- mutational signatures, somatic mutations, cancer genome, APOBEC cytidine deaminases, kataegis, hypermutation, patient age, cancer etiology, cancer types
- MeSH terms
- Aging, Algorithms, Cell Transformation, Neoplastic, Cytidine Deaminase, DNA, DNA Mutational Analysis, Humans, Models, Genetic, Mutagens, Mutation, Neoplasms, Organ Specificity, Transcription, Genetic, Reproducibility of Results, Mutagenesis, Insertional, Mutagenesis, Sequence Deletion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
